Abraxis BioScience, Inc.
Abraxis Provides Overview of ABRAXANE Clinical Studies to Be Presented at the 45th Annual American Society of Clinical Oncology Meeting
Published in Oncology Business Week, May 31st, 2009
Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated biotechnology company, announced that multiple clinical studies of the chemotherapy agent ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) will be presented at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO), being held in Orlando, Florida from May 29 to June 2. Clinical results from 14 company and investigator-sponsored studies will be reported, including an ongoing study evaluating three dosing regimens of nab®-paclitaxel in combination with targeted agent bevacizumab for first-line treatment of metastatic breast cancer.
...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Oncology Business Week
More Articles from Oncology Business Week
- .decimal, Inc.
.decimal, Inc. Gains 510k Clearance from the FDA to Market its p.d Software for Bolus Electron Conformal Therapy in the United States - Advanced Life Sciences Holdings, Inc.
Advanced Life Sciences Announces First Quarter 2009 Financial Results and Financial Outlook - Advaxis, Inc.
Advaxis Explores New Drug Licensing Opportunities - Advaxis, Inc.
Advaxis Scientific Founder Published in Prestigious Peer-Reviewed Journal of Immunology - Adverse Drug Reactions
Creon® (Pancrelipase) Delayed-Release Capsules First and Only Pancreatic Enzyme Product to Receive FDA Approval Under New Guidelines - Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals Reports First Quarter 2009 Financial Results - More from this issue of Oncology Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
